Sunshine Biopharma, Inc.
SBFM
$1.51
-$0.04-2.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 13.75% | -9.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.75% | -9.33% | |||
| Cost of Revenue | 16.75% | -19.83% | |||
| Gross Profit | 7.91% | 21.64% | |||
| SG&A Expenses | 29.06% | 24.52% | |||
| Depreciation & Amortization | 1.24% | 26.92% | |||
| Other Operating Expenses | 92.57% | -61.25% | |||
| Total Operating Expenses | 21.92% | -9.74% | |||
| Operating Income | -84.17% | 12.77% | |||
| Income Before Tax | -132.74% | -17.26% | |||
| Income Tax Expenses | -159.80% | 162.61% | |||
| Earnings from Continuing Operations | -80.18% | -142.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -80.18% | -142.32% | |||
| EBIT | -84.17% | 12.77% | |||
| EBITDA | -89.33% | 14.43% | |||
| EPS Basic | -6.17% | 90.49% | |||
| Normalized Basic EPS | -37.15% | 95.40% | |||
| EPS Diluted | -6.17% | 90.49% | |||
| Normalized Diluted EPS | -37.15% | 95.40% | |||
| Average Basic Shares Outstanding | 69.70% | 2,450.50% | |||
| Average Diluted Shares Outstanding | 69.70% | 2,450.50% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||